Evidence map›Paper›PMID 31647410›Full record

ArticleeLife2019

Structure-based characterization of novel TRPV5 inhibitors.

Taylor Et Hughes, John Smith Del Rosario, Abhijeet Kapoor, Aysenur Torun Yazici, Yevgen Yudin, Edwin C Fluck, Marta Filizola, Tibor Rohacs, Vera Y Moiseenkova-Bell

Open access · goldAbstract read
In one paragraph

Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 75 citations in OpenAlex.

  1. Reevaluating the role of TRPV6 deficiency in human and mouse pancreatitis.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  2. TRPV6-Mediated CaCancers · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Structural insights into TRPV2 modulation by probenecid.Nature structural & molecular biology · 2025
    Article
  9. Forty sites of TRP channel regulation.Current opinion in chemical biology · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Art and Science of Molecular Docking.Annual review of biochemistry · 2024
    Review
  16. Article
  17. Structural mechanism of TRPV5 inhibition by econazole.Structure (London, England : 1993) · 2024
    Article
  18. Role of TRP Channels in Metabolism-Related Diseases.International journal of molecular sciences · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Taylor Et Hughes *Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0002-6064-1227
John Smith Del Rosario *Department of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.ORCID 0000-0003-4947-5835
Abhijeet Kapoor *Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States.ORCID 0000-0002-3606-3463
Aysenur Torun YaziciDepartment of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.ORCID 0000-0002-1715-0107
Yevgen YudinDepartment of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.
Edwin C FluckDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0002-7663-569X
Marta FilizolaDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States.
Tibor RohacsDepartment of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.ORCID 0000-0003-3580-2575
Vera Y Moiseenkova-BellDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0002-0589-4053
Rutgers, The State University of New Jersey · USTranslational Therapeutics (United States) · USIcahn School of Medicine at Mount Sinai · US

Funding

Regulation of sensory TRP channels by phospholipids and G-proteinsR01NS055159 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ROHACS, TIBOR · 2007 to 2022
$5.9M
Regulation of the Intestinal Ca2+ Channels TRPV6R01GM093290 · NIGMS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI CARNEVALE, VINCENZO, ROHACS, TIBOR · 2011 to 2025
$4.9M
Structural biology and molecular biophysics training programT32GM132039 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ben E. Black, Elizabeth Rhoades · 2019 to 2026
$3.3M
Structural Insights into TRPV Channel GatingR01GM103899 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI MOISEENKOVA-BELL, VERA · 2013 to 2021
$3.2M
Transforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9M
Molecular mechanisms of TRPV5 gatingR01GM129357 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI MOISEENKOVA-BELL, VERA · 2018 to 2021
$1.7M
Molecular mechanism of TRPV1 activationR01GM131048 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI CARNEVALE, VINCENZO, ROHACS, TIBOR · 2019 to 2022
$1.4M
National Science Foundation ACI-1053575National Science Foundation MCB080077NIGMS NIH HHS R01 GM093290NIGMS NIH HHS R01GM093290NIGMS NIH HHS R01 GM103899NIGMS NIH HHS R01GM103899NIGMS NIH HHS R01 GM129357NIGMS NIH HHS R01GM129357NIGMS NIH HHS R01 GM131048NIGMS NIH HHS R01GM131048NIGMS NIH HHS T32 GM132039NIH HHS S10 OD018522NINDS NIH HHS R01 NS055159NINDS NIH HHS R01NSNS055159
6 · The paper itself

Abstract

Transient receptor potential vanilloid 5 (TRPV5) is a highly calcium selective ion channel that acts as the rate-limiting step of calcium reabsorption in the kidney. The lack of potent, specific modulators of TRPV5 has limited the ability to probe the contribution of TRPV5 in disease phenotypes such as hypercalcemia and nephrolithiasis. Here, we performed structure-based virtual screening (SBVS) at a previously identified TRPV5 inhibitor binding site coupled with electrophysiology screening and identified three novel inhibitors of TRPV5, one of which exhibits high affinity, and specificity for TRPV5 over other TRP channels, including its close homologue TRPV6. Cryo-electron microscopy of TRPV5 in the presence of the specific inhibitor and its parent compound revealed novel binding sites for this channel. Structural and functional analysis have allowed us to suggest a mechanism of action for the selective inhibition of TRPV5 and lay the groundwork for rational design of new classes of TRPV5 modulators.

Indexed as

Binding SitesCryoelectron MicroscopyEnzyme InhibitorsHEK293 CellsHumansMolecular Docking SimulationProtein ConformationTRPV Cation ChannelsEnzyme InhibitorsTRPV5 protein, humanTRPV Cation ChannelsCryo-EMinhibitorsion channalmolecular biophysicsS. cerevisiaestructural biologystructure-based virtual screeningTRP channelTRPV5

Identifiers

PMID31647410
PMCPMC6834369
OpenAlexW2981514797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.